抗血管内皮生长因子治疗的年龄相关性黄斑变性中黄斑萎缩发生与视网膜下玻璃膜疣样沉积物
研究纳入74只接受抗VEGF治疗至少2年的新生血管性年龄相关性黄斑变性眼,基线SDD存在者46只(63%),平均随访4.7±1.2年期间38只(51%)发生黄斑萎缩;调整年龄、新生血管类型和脉络膜厚度后,基线SDD与黄斑萎缩发生独立相关(OR 3.0,95%CI 1.1-8.5,P=0.0343),SDD累及下方黄斑外区域时关联更强。
要点
- 在接受抗VEGF治疗的新生血管性年龄相关性黄斑变性眼中,基线存在SDD的眼发生黄斑萎缩的几率是无SDD眼的3.0倍(95%CI 1.1-8.5,P=0.0343)。
- 基线SDD位于下方黄斑区和下方黄斑外区时,随访发生黄斑萎缩的几率分别是对应区域无SDD眼的3.0倍和6.5倍。
- 黄斑萎缩发生与特定SDD表型(点状或带状)无关。
核心结论
- 在接受抗VEGF治疗的新生血管性年龄相关性黄斑变性眼中,黄斑萎缩频繁发生,基线SDD与黄斑萎缩发生独立相关,SDD向下方眼底尤其是下方黄斑外区域延伸时后续黄斑萎缩发生的几率更高。
研究设计与样本
- 分析74只无既存黄斑萎缩、接受抗VEGF治疗新生血管性年龄相关性黄斑变性2年或更长的眼。
- 使用至少两种影像模态(谱域光学相干断层扫描、近红外反射、荧光素血管造影和彩色眼底照相)评估SDD存在、表型(点状和带状)和位置、新生血管类型及黄斑萎缩。
- 采用广义估计方程的logistic回归模型评估SDD与黄斑萎缩发生的关联,并调整年龄、新生血管类型和脉络膜厚度。
主要发现
- 基线时46只眼(63%)存在SDD。
- 在平均4.7±1.2年随访期间,38只眼(51%)发生黄斑萎缩。
- 与无SDD眼相比,基线有SDD的眼发生黄斑萎缩的几率为3.0倍(95%CI 1.1-8.5,P=0.0343)。
- 基线SDD位于下方黄斑区和下方黄斑外区的眼,随访时发生黄斑萎缩的几率分别是对应区域无SDD眼的3.0倍(95%CI 1.0-8.9,P=0.0461)和6.5倍(95%CI 1.3-32.4,P=0.0218)。
- 黄斑萎缩发生与特定SDD表型无关。
关键数值与推荐
- 基线SDD存在与黄斑萎缩发生独立相关(OR 3.0,95%CI 1.1-8.5,P=0.0343)。
- 基线SDD位于下方黄斑区与黄斑萎缩发生相关(OR 3.0,95%CI 1.0-8.9,P=0.0461)。
- 基线SDD位于下方黄斑外区与黄斑萎缩发生相关(OR 6.5,95%CI 1.3-32.4,P=0.0218)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the association between presence of subretinal drusenoid deposits (SDD) at baseline in eyes with neovascular age-related macular degeneration (nAMD) with the development of macular atrophy (MA) during anti-vascular endothelial growth factor (VEGF) therapy. METHODS: There were 74 eyes without pre-existing MA receiving anti-VEGF therapy for nAMD for 2 years or longer analyzed. At least two image modalities that included spectral-domain optical coherence tomography, near-infrared reflectance, fluorescein angiography, and color fundus photos were used to assess for SDD presence, phenotype (dot and ribbon), and location, neovascularization type, and MA. Logistic regression models using generalized estimating equations assessed the association between SDD and the development of MA adjusting for age, neovascularization type, and choroidal thickness. RESULTS: SDD were present in 46 eyes (63%) at baseline. MA developed in 38 eyes (51%) during the mean of 4.7 ± 1.2 years of follow-up. Compared with eyes without SDD, those with SDD at baseline were 3.0 times (95% confidence interval [CI] 1.1-8.5, P = 0.0343) more likely to develop MA. Eyes with SDD present in the inferior macula and inferior extramacular fields at baseline were 3.0 times and 6.5 times more likely to develop MA at follow-up than eyes without SDD in these locations (95% CI 1.0-8.9, P = 0.0461 and 95% CI 1.3-32.4, P = 0.0218, respectively). MA development was not associated with a specific SDD phenotype. CONCLUSIONS: MA frequently developed in eyes during anti-VEGF treatment. SDD were independently associated with MA development. The extension of SDD into the inferior fundus, particularly in the inferior extramacular field, conferred higher odds of subsequent MA development.
引用
- Zarubina AV, Gal-Or O, Huisingh CE, et al. Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017. PMID: 29196768. doi:10.1167/iovs.17-22378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。